Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension

By sjmartinez • April 8, 2023

Piccari L, Allwood B, Antoniou K, Chung JH, Hassoun PM, Nikkho SM, Saggar R, Shlobin OA, Vitulo P, Nathan SD, Wort SJ. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension. Pulm Circ. 2023 Apr 1;13(2):e12213. doi: 10.1002/pul2.12213. PMID: 37025209; PMCID: PMC10071306.

Tags: endophenotype, histology, idiopathic pulmonary fibrosis, pathophysiology, Publications, pulmonary vascular disease, Pulmonary, Critical Care & Sleep Medicine

ABCD of IA: A multi-scale agent-based model of T cell activation in inflammatory arthritis

McBride DA, Wang JS, Johnson WT, Bottini N, Shah NJ. ABCD of IA: A multi-scale agent-based model of T cell activation in inflammatory arthritis. Biomater[...]

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan[...]

2-Bromopalmitate depletes lipid droplets to inhibit viral replication

Liu D, Cruz-Cosme R, Wu Y, Leibowitz J, Tang Q. 2-Bromopalmitate depletes lipid droplets to inhibit viral replication. J Virol. 2024 Apr 16;98(4):e0017124. doi: 10.1128/jvi.00171-24.[...]